Only three days ago I predicted that a performance chase is on. Wednesday’s nearly 300-point move in the Dow Jones Industrial Average shows the prediction was spot on. A performance chase buy program triggered the rally and performance chase turned the rally into a buying panic. This was yesterday; now
Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely to succeed. Obamacare in its current form is the walking dead. Trump has said that he will replace Obamacare with something better. In his speeches, Trump outlined certain key points
This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide
This post was just published on ZYX Buy Change Alert. MDVN is the 113th company in our portfolio involved in M&A. The Arora Report’s unrivaled performance in picking companies that get bought out continues. Congratulations to those holding MDVN. MDVN has received an $81.50 cash buyout offer from PFE. MDVN is long
It is official: India is siding with poor cancer patients over profits for multinational drug giants. The Supreme Court of India has rejected a plea by Swiss pharma giant Novartis that ends the seven-year legal battle to restrict Indian companies from copying blood cancer drug Glivec. Novartis had filed a plea with the Supreme
Obama has been re-elected; “Obamacare” is the law of the land. It doesn’t matter if you agree or disagree with Obamacare, you might as well generate big profits from it. Obamacare has been profitable for us. We bought Amerigroup Corp. AGP at $22.05, and, as of this writing, the stock
A popular axiom among long-only investors is to “buy low sell high.” For those investors who are equally interested in making money from both markets going up and markets going down, the parallel axiom is, “short-sell high and buy-to-cover low.” In the short-term, the stock market is overbought, and it
In 1971, a Japanese biochemist, Akira Endo, started work on what turned out to be the next big thing in the prevention of heart attacks and strokes, known as statins. In 1978, Merck (MRK) isolated lovastatin from fungusAspergillus terreus. Lovastatin is naturally contained in red yeast rice, a traditional Chinese fermented rice